Sana Biotechnology (SANA) CEO granted 200,000 RSUs and 900,000 stock options

Rhea-AI Filing Summary

Sana Biotechnology President & CEO Steve Harr received new equity awards. On March 5, he was granted 200,000 restricted stock units and stock options for 900,000 shares of Sana common stock, both at a per-share exercise price of $0.00.

The 200,000 restricted stock units each represent a right to receive one share of Sana common stock and vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030, if he continues to serve the company. The 900,000-share stock option vests as to 25% of the underlying shares on March 5, 2027, then in 36 equal monthly installments thereafter, also conditioned on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Harr Steve

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	200,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	900,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 200,000 shares (Direct); Stock Option (Right to Buy) — 900,000 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harr Steve

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/05/2026		A		200,000		(2)	(2)	Common Stock	200,000	$0.00	200,000	D
Stock Option (Right to Buy)	$3.41	03/05/2026		A		900,000		(3)	03/04/2036	Common Stock	900,000	$0.00	900,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

2. The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

3. The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Remarks:

	/s/ Aaron M. Grossman, Attorney-in-Fact for Steve Harr	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Sana Biotechnology (SANA) CEO Steve Harr receive?

Sana Biotechnology’s CEO Steve Harr received 200,000 restricted stock units and stock options for 900,000 shares. The RSUs convert into common stock if vesting conditions are met, while the options give him the right to buy Sana shares once they vest and become exercisable.

How do the new restricted stock units for Sana (SANA) CEO vest?

The 200,000 restricted stock units granted to Sana’s CEO vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030. Vesting requires his continuous service to Sana as an employee, consultant, director or officer through each vesting date.

What is the vesting schedule for Steve Harr’s 900,000 Sana (SANA) stock options?

The 900,000-share stock option for Steve Harr vests 25% on March 5, 2027, with the remaining shares vesting in 36 equal monthly installments after that date. Vesting is conditioned on his continued service to Sana in an eligible role throughout the vesting period.

What does each restricted stock unit for Sana Biotechnology (SANA) represent?

Each restricted stock unit granted to Steve Harr represents a contingent right to receive one share of Sana Biotechnology common stock. These units only convert into shares if the specified time-based vesting conditions and continuous service requirements are satisfied on each vesting date.

Are Steve Harr’s new Sana (SANA) awards direct or indirect ownership?

The Form 4 indicates Steve Harr’s newly granted restricted stock units and stock options are held as direct ownership. There are no footnotes stating that another entity holds voting or investment power, so the awards are attributed directly to him under the filing’s disclosures.